CBP-4888
CBP-4888 is currently being evaluated in a global clinical development program to determine its ability to treat women with sFlt1-mediated preterm preeclampsia, a serious and life threatening pregnancy complication.
CBP-4888 is a novel short-interfering RNA (siRNA) drug candidate specifically designed to selectively reduce overexpression of the protein sFlt-1 (soluble fms-like tyrosine kinase-1) — a key pathogenic driver of preeclampsia.
When produced in excess by the placenta, sFlt1 is toxic, severely damaging the mother’s blood vessels and impairing the growth of new ones. This overproduction of sFlt-1 and subsequent vascular damage create the widespread maternal signs and symptoms of preeclampsia and often result in premature delivery of the baby.
By precisely reducing excessive sFlt-1 production, CBP-4888 is being investigated for the potential to ameliorate the acute maternal symptoms of preterm preeclampsia and, in turn, improve maternal, fetal and neonatal outcomes around the world.
Read About Our Science
Learn More
Contact Us
50 Beharrell St, Unit B
Concord, MA 01742